On December 1, 2022 Evotec partner Kazia Therapeutics Limited ("Kazia", NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported the publication of positive pre-clinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer (Press release, Evotec, NOV 30, 2022, View Source [SID1234624732]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication, by Michael Paillasse and colleagues, summarises a large body of pre-clinical research conducted principally by scientists at Evotec SE and at the University Cancer Institute of Toulouse – Oncopole over a period of several years. It is now published in Cancer Research Communications, a recently-launched journal published by the American Association of Cancer Research ("AACR"). The data formed the basis of Kazia’s in-licensing of EVT801 from Evotec in 2021 and has since supported transition of the compound into an ongoing Phase I clinical trial in patients with advanced solid tumours.

The publication may be accessed via the journal website at
View Source

For further information, please follow this link to the full version of the press release from Kazia Therapeutics.